Back to Search
Start Over
EGLP-1 lowers body weight better than exendin-4 by reducing food intake and increasing basal energy expenditure in diet-induced obese mice.
- Source :
-
Experimental cell research [Exp Cell Res] 2021 Feb 01; Vol. 399 (1), pp. 112454. Date of Electronic Publication: 2020 Dec 25. - Publication Year :
- 2021
-
Abstract
- It is well known that GLP-1 activates GLP-1R to reduce body weight by inhibiting eating. GLP-1 is cleaved by the neutral endopeptidase (NEP) 24.11 into a pentapeptide GLP-1 (32-36) amide, which increases basal energy expenditure and inhibits weight gain in obese mice. It is well known that GLP-1 analogs can reduce weight by suppressing eating. However, there are few reports of reducing weight through the dual effects of inhibiting eating and increasing basic energy. Here, we report the peptide EGLP-1, a GLP-1 analogue, which can reduce food intake and increase basal energy expenditure. In C2C12 myotubes, EGLP-1 can increase both phosphorylation of acetyl CoA carboxylase (ACC) and the ratio between phosphorylation of ACC and the total expression of ACC (pACC/ACC). In diet-induced obese mice, EGLP-1 is more effective than exendin-4 in reducing body weight, reducing fat mass and improving hepatic steatosis. At the same time, EGLP-1 can improve hyperglycemia, reduce food intake, and improve insulin resistance, just like exendin-4. In addition, EGLP-1, not exendin-4, can improve physiological parameters associated with lipid metabolism and increase oxygen consumption by increasing uncoupling proteins 3 (UCP3) expression and pACC/ACC ratio in skeletal muscle. Taken together, this data showed that EGLP-1 is able to reduce body weight by reducing food intake and increasing basal energy expenditure, suggesting it may be more effective in treating diabetic and non-diabetic overweight or obese people than pure GLP-1R agonist exendin-4.<br /> (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Subjects :
- Animals
Anti-Obesity Agents pharmacology
Cells, Cultured
Diet, High-Fat
Eating physiology
Exenatide pharmacology
Exenatide therapeutic use
Glucagon-Like Peptide 1 chemistry
Glucagon-Like Peptide 1 therapeutic use
Male
Mice
Mice, Inbred C57BL
Mice, Obese
Obesity drug therapy
Obesity etiology
Peptide Fragments pharmacology
Peptide Fragments therapeutic use
Body Weight drug effects
Eating drug effects
Energy Metabolism drug effects
Glucagon-Like Peptide 1 pharmacology
Obesity metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1090-2422
- Volume :
- 399
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Experimental cell research
- Publication Type :
- Academic Journal
- Accession number :
- 33359447
- Full Text :
- https://doi.org/10.1016/j.yexcr.2020.112454